Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

Abstract Background The Janus kinase/signal transducer and activator of transcription (JAK‐STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, t...

Full description

Bibliographic Details
Main Authors: David Fogelman, Antonio Cubillo, Pilar García‐Alfonso, María Luisa Limón Mirón, John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, Jose M. Vieitez, Allen Cohn, Gene Saylors, Albert Assad, Julie Switzky, Li Zhou, Johanna Bendell
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Cancer Medicine
Subjects:
clinical trial
colorectal cancer
inflammation
JAK1 protein tyrosine kinase
JAK2 protein tyrosine kinase
ruxolitinib
Online Access:https://doi.org/10.1002/cam4.1703

Internet

https://doi.org/10.1002/cam4.1703

Similar Items